Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer

  • William K. Oh
  • , Matthew D. Galsky
  • , Walter M. Stadler
  • , Sandy Srinivas
  • , Franklin Chu
  • , Glenn Bubley
  • , J. Goddard
  • , Joi Dunbar
  • , Robert W. Ross

Research output: Contribution to journal › Article › peer-review

67 Scopus citations

Fingerprint

Dive into the research topics of 'Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science